Pain Therapeutics has received a $1.8 million research grant from the National Institutes of Health (NIH) to support the development of a technology to diagnose Alzheimer’s disease (AD) in early stages based on a simple blood test. AD is a progressive disorder, meaning it slowly destroys memory and cognitive skills.
Older people — ages 60 to 75 — in good cognitive health but with two copies of the “risk gene” for Alzheimer’s disease (AD) are being asked to take part in Generation Study, a collaborative and global research project investigating treatments that might stop the disease from developing. Two copies of the APOE4 gene are inherited, one from…
White women whose genes put them at risk of developing Alzheimer’s disease are more likely than white men with similar risk genes to be diagnosed between the ages of 65 and 75, a study drawing on patient data in North America and Europe reports. Overall, between the ages of 55 and 85, Caucasian…
Vanderbilt University researchers have developed a potential therapy for Alzheimer’s disease (AD) that has shown promising results in brain health. The investigative treatment, a molecule called VU319, is expected to fill a long-needed gap for Alzheimer’s patients by improving memory, attention, and brain functioning. The U.S. Food and Drug Administration…
A functional brain imaging study led by scientists at the Amen Clinics in Newport Beach, California, has qualified differences between women’s and men’s brains with relevant findings for Alzheimer’s disease research. The study, “Gender-Based Cerebral Perfusion Differences in 46,034 Functional Neuroimaging Scans,” appeared in the Journal of Alzheimer’s Disease. Understanding…
Loyola Medicine will participate in a landmark $100 million study called “Imaging Dementia – Evidence for Amyloid Scanning (IDEAS)” to evaluate the effectiveness of using positron emission tomography (PET) scans to detect Alzheimer’s disease (AD). The IDEAS (NCT02420756)…
VTv Therapeutics has received another U.S. patent for azeliragon, an Alzheimer’s treatment that targets a receptor involved in the disease’s inflammation. Azekuragan is an antagonist of the advanced glycation endproducts, or RAGE, receptor, meaning that it prevents the receptor from acting. Found in low levels in a healthy brain, RAGE…
The Gerontological Society of America has developed a free online toolkit to help primary-care doctors detect and diagnose cognitive impairment, dementia and Alzheimer’s disease, the most common type of dementia. The toolkit is based on a four-step process for detecting cognitive impairment and diagnosing dementia earlier. The society named…
The Alzheimer’s Research and Prevention Foundation (ARPF) will launch a new Brain Longevity Therapy Training Program to educate wellness and healthcare workers on the four pillars of Alzheimer’s disease prevention: diet, stress management, exercise and spiritual fitness. The spiritual fitness segment focuses on yoga and meditation techniques,…
A plan to test a multi-dimensional, lifestyle-based approach to preventing cognitive decline and dementia in people at risk of Alzheimer’s was one of the important revelations that surfaced at the 2017 Alzheimer’s Association International Conference, experts said. Other convention highlights that the Alzheimer’s Association identified included: Interim results of a…
Get regular updates to your inbox.